Everolimus improves the efficacy of dasatinib in PDGFRa-driven glioma

Al's Comment:

 Look at your pathology report to see if you have the PDGFRα mutation...  if so it might be worth considering this combination!  It is early work but they did the research the right way - they came up with a theory, tested it in the lab and in animals, then tried it on a small group of people and it did pretty well.   The Musella Foundation helped support this project through our collaboration with the DIPG Collaborative.


Posted on: 07/03/2020

Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma

 


Click HERE to return to brain tumor news headlines